HCM

Quote

Short

News

Articles

Message Board

HUTCHMED (China) Limited (NASDAQ : HCM ) News

News Releases

HCM News Releases

July 02, 2026 04:30:00 am

GlobeNewswire

HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification

June 30, 2026 04:30:00 am

GlobeNewswire

HUTCHMED to Announce 2026 Half-Year Financial Results

June 24, 2026 08:00:00 pm

GlobeNewswire

HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib in Intrahepatic Cholangiocarcinoma Presented at ESMO Gastrointestinal Cancers Congress 2026

June 11, 2026 08:00:00 pm

GlobeNewswire

HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress

May 28, 2026 06:15:03 pm

KlickAnalytics

HCM Price Target Alert: $13.60. Issued by Morgan Stanley

May 21, 2026 08:00:00 pm

GlobeNewswire

HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting

May 21, 2026 06:00:00 am

GlobeNewswire

HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma

April 29, 2026 08:35:00 am

GlobeNewswire

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing

April 29, 2026 06:00:00 am

GlobeNewswire

HUTCHMED Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

April 23, 2026 08:35:00 am

GlobeNewswire

International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on April 28, 2026

	Next 10

Subscribe to Our Newsletter

Download The Market Wire News App

Link Market Wire News to Your X Account